Blueprint Medicines Corporation (BIT:1BPMC)

Market Cap	7.23B
Revenue (ttm)	520.07M
Net Income (ttm)	-144.08M
Shares Out	n/a
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	105.10
Day's Range	n/a
52-Week Range	75.82 - 111.75
Beta	n/a
RSI	53.01
Earnings Date	Jul 31, 2025

About Achilles Therapeutics

Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung canc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 649
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BPMC

Financial Performance

In 2024, Blueprint Medicines's revenue was $508.82 million, an increase of 104.04% compared to the previous year's $249.38 million. Losses were -$67.09 million, -86.77% less than in 2023.